Shares of Surgery Partners, Inc. (NASDAQ:SGRY - Get Free Report) have earned an average recommendation of "Moderate Buy" from the nine analysts that are covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $36.63.
A number of equities research analysts have commented on the company. Bank of America started coverage on Surgery Partners in a report on Monday, December 16th. They issued a "buy" rating and a $30.00 target price for the company. Macquarie dropped their price target on Surgery Partners from $34.00 to $33.00 and set an "outperform" rating for the company in a research report on Tuesday, March 11th. Royal Bank of Canada restated an "outperform" rating and set a $35.00 price objective on shares of Surgery Partners in a research report on Tuesday. Finally, JPMorgan Chase & Co. decreased their price objective on Surgery Partners from $38.00 to $28.00 and set a "neutral" rating on the stock in a research note on Tuesday, December 3rd.
Read Our Latest Research Report on Surgery Partners
Surgery Partners Stock Performance
Shares of NASDAQ:SGRY traded up $0.10 during midday trading on Monday, hitting $24.12. The stock had a trading volume of 376,647 shares, compared to its average volume of 1,059,884. The company has a market capitalization of $3.08 billion, a PE ratio of -50.25, a P/E/G ratio of 19.21 and a beta of 2.73. Surgery Partners has a 1 year low of $19.50 and a 1 year high of $33.97. The stock has a 50 day moving average price of $24.16 and a two-hundred day moving average price of $25.64. The company has a current ratio of 1.80, a quick ratio of 1.66 and a debt-to-equity ratio of 0.99.
Surgery Partners (NASDAQ:SGRY - Get Free Report) last released its earnings results on Monday, March 3rd. The company reported $0.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.01. The company had revenue of $864.40 million for the quarter, compared to analysts' expectations of $828.09 million. Surgery Partners had a positive return on equity of 2.85% and a negative net margin of 2.03%. As a group, equities analysts predict that Surgery Partners will post 0.67 earnings per share for the current fiscal year.
Insider Activity
In related news, insider Harrison R. Bane sold 56,315 shares of the stock in a transaction on Friday, February 7th. The stock was sold at an average price of $25.64, for a total value of $1,443,916.60. Following the transaction, the insider now directly owns 107,037 shares of the company's stock, valued at approximately $2,744,428.68. This trade represents a 34.47 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Marissa Brittenham sold 3,156 shares of Surgery Partners stock in a transaction on Monday, March 10th. The shares were sold at an average price of $24.09, for a total value of $76,028.04. Following the completion of the transaction, the insider now owns 63,408 shares in the company, valued at $1,527,498.72. The trade was a 4.74 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 106,622 shares of company stock valued at $2,717,860 in the last 90 days. 2.30% of the stock is currently owned by insiders.
Hedge Funds Weigh In On Surgery Partners
Institutional investors and hedge funds have recently bought and sold shares of the stock. Principal Financial Group Inc. purchased a new position in shares of Surgery Partners in the third quarter valued at $1,469,000. Natixis Advisors LLC boosted its position in Surgery Partners by 3.0% in the 3rd quarter. Natixis Advisors LLC now owns 12,828 shares of the company's stock valued at $414,000 after buying an additional 376 shares during the last quarter. Pathstone Holdings LLC grew its stake in shares of Surgery Partners by 30.9% during the third quarter. Pathstone Holdings LLC now owns 57,347 shares of the company's stock valued at $1,849,000 after acquiring an additional 13,534 shares in the last quarter. Intech Investment Management LLC purchased a new stake in shares of Surgery Partners during the third quarter worth about $627,000. Finally, Charles Schwab Investment Management Inc. increased its stake in Surgery Partners by 5.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 772,746 shares of the company's stock valued at $24,913,000 after purchasing an additional 38,810 shares during the last quarter.
About Surgery Partners
(
Get Free ReportSurgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.
See Also
Before you consider Surgery Partners, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Surgery Partners wasn't on the list.
While Surgery Partners currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
